Podcasts

Andres Cervantes, MD, PhD, Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer

01/19/2021

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and discusses new advancements in the treatment of HER2+ gastric cancer.

Dr Cervantes highlights the...

01/19/2021

Oncology

Podcasts

Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies

12/17/2020

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and...

Jan A. Burger, MD, PhD, MD...

12/17/2020

Oncology

Podcasts

Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML

12/11/2020

In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.

In this podcast, Dr Hochhaus...

12/11/2020

Oncology

Podcasts

Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP

11/30/2020

Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.

Dr Hochhaus discusses the use of...

11/30/2020

Oncology

$Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM$

Podcasts

Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM

10/28/2020

In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.

In this podcast, Dr Raje...

10/28/2020

Oncology

Podcasts

BCMA-Directed CAR-T Therapy Shows Promise in Pretreated MM

10/22/2020

Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.

Jesus Berdeja, MD, discusses the...

10/22/2020

Oncology

Podcasts

Navigating the MM Treatment Landscape

10/20/2020

Natalie S. Callander, MD, discusses individualized treatment approaches for patients with relapsed or refractory MM.

Natalie S. Callander, MD,...

10/20/2020

Oncology

Podcasts

Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress

10/19/2020

John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.

John Leonard, MD, discusses what...

10/19/2020

Oncology

Podcasts

Episode 4: Evolving Therapies for Ewing Sarcoma

10/15/2020

In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.

In the fourth episode, Brian Van...

10/15/2020

Oncology

Podcasts

Abhishek Maiti, MBBS, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML

10/15/2020

Dr Maiti discusses findings from a trial of 10-day decitabine plus venetoclax for patients with newly diagnosed, intensive chemo–ineligible, and relapsed/refractory AML.

Dr Maiti discusses findings from...

10/15/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology